Lexeo's IPO Raises $100M for Gene Therapies That Treat the Heart, Protect the Brain
The gene therapy programs of Lexeo Therapeutics span rare forms of cardiomyopathy and certain types of Alzheimer’s disease. But Lexeo’s IPO comes as a rival gene therapy developer sues the biotech, claiming its work employs stolen trade secrets.
New York United States Cornell University Nolan Townsend Rocket Pharmaceuticals Rocket Pharmaceuticals Inc
Source: medcitynews.com